www.pharmatechoutlook.comE DI T IO NISSN 2644-2787AUGUST - 07 - 2023$15Joerg Ahlgrimm,CEOSKpharmtecoMAXIMIZING PACE AND INNOVATION IN DRUG DEVELOPMENTACTIVE PHARMACEUTICAL INGREDIENTS
Page 2 >